vortioxetine sold brand names trintellix brintellix among others medication used treat major depressive effectiveness viewed similar taken common side effects include nausea vomiting constipation sexual serious side effects may include suicide age serotonin syndrome bleeding mania withdrawal syndrome may occur medication abruptly stopped dose use pregnancy breastfeeding generally classified serotonin modulator vortioxetines mechanism action entirely understood believed related increasing serotonin levels possibly interacting certain receptors approved medical use united states commonly prescribed medication united states million vortioxetine used treatment major depressive effectiveness appears similar effect size described vortioxetine may used treatments cochrane review vortioxetine determined place treatment severe depression unclear due lowquality evidence study needed comparing vortioxetine selective serotonin reuptake inhibitors ssris typical firstline vortioxetine appears work depressed patients vortioxetine also used offlabel review found useful generalized anxiety disorder mg doses mg doses metaanalysis found vortioxetine produce statistically significant results placebo symptoms quality life remission rates generalized anxiety disorder however metaanalysis supported use efficacy vortioxetine generalized anxiety disorder though stated research necessary strengthen systematic review metaanalysis concluded uncertainty effectiveness vortioxetine anxiety due existing evidence network metaanalysis randomized controlled trials vortioxetine associated among lowest remission rates generalized anxiety disorder included medications odds ratio vortioxetine range odds ratios agents vortioxetine contraindicated taking monoamine oxidase inhibitors maois due possibility serotonin common side effects reported vortioxetine nausea vomiting constipation sexual dysfunction among exceptions nausea sexual dysfunction side effects reported less equal study participants given significant percentages placebotreated participants also report side discontinuation treatment due adverse effects clinical trials vortioxetine versus sexual dysfunction decreased libido abnormal orgasm delayed ejaculation erectile dysfunction wellknown side effects ssris reuptake inhibitors clinical trials sexual dysfunction occurred often vortioxetine placebo appeared specific incidencesspelling treatmentemergent sexual dysfunction measured arizona sexual experience scale asex placebo vortioxetine dosage range incidence sexual dysfunction vortioxetine similar snri duloxetine incidence used dosage however treatmentemergent sexual dysfunction caused prior ssri better improved switching vortioxetine switching ssri another study vortioxetine dosage mgday though mgday produced less sexual dysfunction ssri findings suggest although vortioxetine still cause sexual dysfunction may cause somewhat less sexual dysfunction ssris might useful alternative option people experiencing sexual dysfunction rates voluntarily spontaneously reported sexual dysfunction vortioxetine much lower asex ranging vortioxetine versus placebo clinical significant changes body weight gain loss observed vortioxetine clinical however reports come users regarding weight gainloss since approval vortioxetine based preliminary clinical studies vortioxetine may cause less emotional blunting ssris vortioxetine used combination serotonergic drugs like maois ssris may result serotonin vortioxetine metabolized primarily cytochrome enzyme inhibitors inducers may modify pharmacokinetics vortioxetine necessitate dosage bupropion strong inhibitor found increase peak levels vortioxetine total vortioxetine levels bupropion dosed mgday vortioxetine dosed incidence side effects vortioxetine like nausea headache vomiting insomnia correspondingly increased strong inhibitors like fluoxetine paroxetine quinidine may similar influences pharmacokinetics vortioxetine recommended dosage vortioxetine reduced half administered combination lesser interactions additionally identified vortioxetine cytochrome inhibitors ketoconazole rifampicin strong broad cytochrome inducer though notably found decrease peak levels vortioxetine total levels vortioxetine rifampicin dosed mgday vortioxetine similar influences vortioxetine pharmacokinetics may also occur strong cytochrome inducers like carbamazepine recommended increasing vortioxetine dosage considered given combination strong cytochrome maximum recommended dose exceed three times original vortioxetine vortioxetine metabolites show meaningful interactions variety assessed cytochrome enzymes transporters eg pglycoprotein hence vortioxetine expected importantly influence pharmacokinetics combination vortioxetine maois including maois like linezolid intravenous methylene blue may cause serotonin syndrome risk serotonin syndrome may also increased vortioxetine combined serotonergic drugs like ssris snris tricyclic antidepressants tcas triptans tramadol tryptophan buspirone st johns wort fentanyl lithium among however vortioxetine considered contraindicated serotonergic medications besides vortioxetine increases serotonin concentrations brain inhibiting reuptake synapse also modulates activates blocks certain serotonin receptors puts class serotonin modulators stimulators also includes specifically vortioxetine serotonin reuptake inhibitor agonist serotonin receptor partial agonist receptor antagonist serotonin receptors well apparent ligand terms functional activity however vortioxetine appears much potent serotonin reuptake inhibition receptor antagonism interactions serotonin whereas vortioxetine values nm sert nm receptor values nm translates selectivity sert inhibition selectivity antagonism activities serotonin antagonism appears better effect rem sleep compared claimed serotonin transporter sert receptor may primarily occupied lower clinical doses vortioxetine receptors may additionally occupied higher occupancy serotonin transporter vortioxetine young men found highest raphe nucleus median occupancies days administration mgday another study serotonin transporter occupancy men mgday vortioxetine mgday may produce antidepressant effects result sert occupancy low apparent contrast ssris snris appear require minimum occupancy antidepressant findings suggestive antidepressant effects vortioxetine may mediated serotonin receptor interactions addition serotonin reuptake study found significant occupancy receptor vortioxetine mgday days suggests least specific serotonin receptor may involved clinical pharmacology however methodological concerns noted may limit interpretability occupancy serotonin receptors like vortioxetine humans seem relation preceding contribution serotonin receptor interactions antidepressant effects vortioxetine unknown remains uncertainties remain whether vortioxetine indeed clinically multimodal antidepressant whether effectively another selective serotonin reuptake antagonism receptor found enhance increase brain serotonin levels produced serotonin reuptake inhibition animal whether receptor antagonism vortioxetine likewise humans contributes clinical antidepressant efficacy ssris receptor agonists often produce nausea side effect whereas receptor antagonists like ondansetron antiemetics found effective treating ssriinduced thought receptor antagonism vortioxetine would reduce incidence nausea relative however clinical trials found significant dosedependent rates nausea vortioxetine appeared comparable found snri vortioxetine wellabsorbed taken orally oral bioavailability systemically detectable single oral dose peak levels vortioxetine reached within hours postdose single multiple steadystate levels vortioxetine generally reached within weeks administration individuals reaching steady state days steadystate peak levels vortioxetine doses mgday ngml accumulation index vortioxetine areaunderthecurve levels single dose versus steady state loading dose given intravenously found achieve steadystate levels rapidly oral vortioxetine pharmacokinetics vortioxetine known linear dose proportional range mg single doses mg multiple food influence pharmacokinetics apparent volume distribution vortioxetine large ranges l single multiple doses mg vortioxetine extensive extravascular plasma protein binding vortioxetine approximately free vortioxetine extensively metabolized oxidation via cytochrome enzymes subsequent glucuronidation via primary enzyme involved metabolism vortioxetine others including also also metabolized alcohol dehydrogenase aldehyde dehydrogenase aldehyde six metabolites vortioxetine major metabolite vortioxetine lu inactive minor active metabolite lu thought cross remaining metabolites glucuronide hence vortioxetine thought primarily responsible pharmacological estimated total clearance vortioxetine ranges elimination halflife vortioxetine hours range hours single multiple elimination vortioxetine almost entirely via liver rather kidneys approximately vortioxetine recovered singledose excretion study days urine genetic variations cytochrome enzymes influence exposure extensive metabolizers approximately higher clearance vortioxetine poor estimated clearance rates lh ultrarapid metabolizers extensive metabolizers intermediate metabolizers poor areaunderthecurve levels vortioxetine lower ultrarapid metabolizers extensive metabolizers though significant overlap due interindividual dosage adjustment ultrarapid metabolizers considered vortioxetine exposure poor metabolizers expected approximately twice high extensive depending individual response dosage adjustment may considered poor metabolizers maximum recommended dosage mgday known addition extensive metabolizers higher clearance vortioxetine poor however considered clinically important dose adjustment considered necessary based vortioxetine bisarylsulfanyl amine well piperazine acid dissociation constant pka values vortioxetine hydrobromide determined according australian public assessment vortioxetine discovered scientists lundbeck reported rationale synthesis drug called lu compound phase ii clinical trials lundbeck takeda entered partnership takeda paid lundbeck million upfront promises million milestone payments takeda agreed pay remaining cost developing drug companies agreed copromote drug us japan lundbeck would receive royalty sales deal included another drug candidate tedatioxetine lu could expanded include two lundbeck vortioxetine approved us food drug administration fda treatment major depressive disorder mdd adults september approved european union later made pharmaceutical companies lundbeck vortioxetine previously sold brand name brintellix united states may us food drug administration fda approved name change trintellix order avoid confusion bloodthinning medication brilinta india sold name vortioxetine development treatment generalized anxiety attentiondeficit hyperactivity disorder development indications august vortioxetine remains development treatment anxiety disorders bingeeating disorder bipolar phase ii clinical trials also interest vortioxetine potential treatment social neuropathic cognitive enhancement major httpsenwikipediaorgwikivortioxetine